Compass Pathways plc announced that the U.S. Food and Drug Administration has granted the company a rolling review request for the New Drug Application (NDA) for COMP360, its synthetic psilocybin therapy for treatment‑resistant depression (TRD). The FDA also selected COMP360 for the Commissioner's National Priority Voucher (CNPV) program, a fast‑track pathway that can provide a 90‑day review window for drugs that address unmet medical needs.
The rolling review allows Compass to submit completed sections of the NDA as they are finished, potentially shortening the overall review period compared to a traditional full‑submission approach. The CNPV designation signals the agency’s confidence in the clinical data and the therapeutic potential of COMP360, and it can accelerate the path to market approval once the NDA is filed.
COMP360 has generated positive data from two large, well‑controlled Phase 3 clinical trials involving more than 1,000 participants. It is the first classic psychedelic to consistently achieve statistically significant and clinically meaningful results in two Phase 3 studies, with a generally well‑tolerated safety profile. The treatment can produce rapid effects within one day and durable benefits lasting at least through six months for responders.
CEO Kabir Nath said, "As the most advanced company in the classic psychedelics field, Compass has generated positive data from two large, well controlled Phase 3 clinical trials. Based on the strength of our data, the FDA granted us a rolling NDA submission and review." He added, "Patients with TRD often endure years of persistent suffering with limited options, and the need for meaningful innovation for these patients has never been more urgent. We are well advanced in our commercial preparations and the CNPV could further accelerate momentum toward bringing our transformative treatment, if approved, to patients who have been waiting far too long."
The announcement was welcomed by investors, with analysts noting the accelerated regulatory pathway and the potential for early market entry. The rolling review and CNPV status enhance Compass’s competitive positioning against other psychedelic‑based treatments and reinforce confidence in the company’s commercial trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.